SCHOLAR ROCK HOLDING CORPORATION Debt Securities, Available-for-sale, Amortized Cost
SCHOLAR ROCK HOLDING CORPORATION (SRRK) had Debt Securities, Available-for-sale, Amortized Cost of $55.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $55.01M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $49.38M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $43.94M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $82.74M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $55.01M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $49.38M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $43.94M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $82.74M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $142.03M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $226.32M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $259.24M 10-K · filed 2026-03-03 |
| 2024-09-30 | $62.55M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $97.18M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $146.50M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $177.99M 10-K · filed 2025-02-27 |
| 2023-09-30 | $151.06M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $140.73M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $124.33M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $212.97M 10-K · filed 2024-03-19 |
| 2022-09-30 | $211.52M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $65.04M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $110.19M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $40.19M 10-K · filed 2023-03-07 |
| 2021-09-30 | $70.30M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $75.29M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $155.56M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $180.68M 10-K · filed 2022-03-07 |
| 2020-09-30 | $60.03M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $26.00M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $64.98M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $121.10M 10-K · filed 2021-03-09 |
| 2019-09-30 | $143.41M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $71.28M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $92.65M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $60.58M 10-K · filed 2020-03-12 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 |
| 2017-12-31 | $1.50M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |